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The poor prognosis for patients with diffuse large B cell lymphoma (DLBCL) who relapse within 1 year of
initial diagnosis after ﬁrst-line rituximab-based chemo-immunotherapy has created controversy about the
role of autologous transplantation (HCT) in this setting. We compared autologous HCT outcomes for che-
mosensitive DLBCL patients between 2000 and 2011 in 2 cohorts based on time to relapse from diagnosis. The
early rituximab failure (ERF) cohort consisted of patients with primary refractory disease or those with ﬁrst
relapse within 1 year of initial diagnosis. The ERF cohort was compared with those relapsing >1 year after
initial diagnosis (late rituximab failure [LRF] cohort). ERF and LRF cohorts included 300 and 216 patients,dgments on page 1735.
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Diffuse large B cell lymphoma
Aggressive lymphoma
Non-Hodgkin lymphomarespectively. Nonrelapse mortality (NRM), progression/relapse, progression-free survival (PFS), and overall
survival (OS) of ERF versus LRF cohorts at 3 years were 9% (95% conﬁdence interval [CI], 6% to 13%) versus 9%
(95% CI, 5% to 13%), 47% (95% CI, 41% to 52%) versus 39% (95% CI, 33% to 46%), 44% (95% CI, 38% to 50%) versus
52% (95% CI, 45% to 59%), and 50% (95% CI, 44% to 56%) versus 67% (95% CI, 60% to 74%), respectively. On
multivariate analysis, ERF was not associated with higher NRM (relative risk [RR], 1.31; P ¼ .34). The ERF
cohort had a higher risk of treatment failure (progression/relapse or death) (RR, 2.08; P < .001) and overall
mortality (RR, 3.75; P < .001) within the ﬁrst 9 months after autologous HCT. Beyond this period, PFS and OS
were not signiﬁcantly different between the ERF and LRF cohorts. Autologous HCT provides durable disease
control to a sizeable subset of DLBCL despite ERF (3-year PFS, 44%) and remains the standard-of-care in
chemosensitive DLBCL regardless of the timing of disease relapse.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose therapy (HDT) with autologous hematopoi-
etic cell transplantation (HCT) is the treatment of choice for
patients with relapsed chemosensitive diffuse large B cell
lymphoma (DLBCL) and appears to be curative for 40% to
45% of the patients [1-3]. The incorporation of rituximab in
ﬁrst-line chemotherapy has signiﬁcantly improved sur-
vival outcomes of both elderly and younger DLBCL patients
[4-7]. However, despite modern chemo-immunotherapies,
some patients still do not achieve complete remission [CR]
(induction failure), or relapse after the initial chemo-
therapy [8].
Autologous HCT is frequently considered for patients
with primary refractory DLBCL (ie, patients not achieving a
CR after ﬁrst-line therapies). Registry data from the pre-
rituximab era [9] suggested that such high-risk primary
refractory DLBCL patients can achieve durable disease
control with HDT and autologous HCT, provided they
demonstrate evidence of chemosensitive disease after pre-
transplantation salvage therapies (5-year progression-free
survival [PFS] and overall survival [OS] of 31% and 37%,
respectively). These data [1,2,9], derived mainly before the
advent of chemo-immunotherapies, form the basis of cur-
rent clinical practice of considering HDT in relapsed che-
mosensitive DLBCL patients, including those with primary
refractory disease. However, the validity of this paradigm in
patients treated with rituximab-based ﬁrst-line chemo-
immunotherapies has come under recent scrutiny, owing
largely to observations made in the Collaborative Trial in
Relapsed Aggressive Lymphoma (CORAL) study [8,10]. The
CORAL trial [11] data, although in general supporting the
role of autologous HCT in relapsed chemosensitive DLBCL,
identiﬁed a subset of high-risk patients (ie, those treated
with rituximab-based ﬁrst-line chemo-immunotherapies
and either not achieving CR or experiencing a relapse
within 1 year of initial diagnosis) with an extremely poor
prognosis with standard salvage approaches (3-year PFS of
w20%) [11]. The disappointing outcomes of DLBCL patients
experiencing early rituximab failure (ERF) in this study have
led several groups to question the utility of HDT in this
particular setting [10]. We, therefore, used the observational
database of the Center for International Blood and Marrow
Transplant Research (CIBMTR) to evaluate the role of
autologous HCT in DLBCL patients experiencing ERF
(deﬁned as DLBCL patients treated with rituximab-based
ﬁrst-line chemo-immunotherapies, who either had pri-
mary refractory disease or relapsed within 1 year of
initial diagnosis), relative to the outcomes of patients
receiving ﬁrst-line rituximab-based therapies and relapsing
>12 months after initial diagnosis (late rituximab failure
[LRF]).MATERIALS AND METHODS
Data Sources
The CIBMTR is a working group of more than 450 transplantation cen-
ters worldwide that contribute detailed data on HCTs to a statistical center at
the Medical College of Wisconsin. Centers report HCTs consecutively, with
compliance monitored by on-site audits. Patients are followed longitudi-
nally with yearly follow-up. Observational studies by the CIBMTR are per-
formed in compliance with federal regulations with ongoing review by the
institutional review board of the Medical College of Wisconsin.
Patients
The study population included all patients with a histologically proven
diagnosis of DLBCL treated with rituximab-based ﬁrst-line chemo-
immunotherapies, who underwent an autologous HCT reported to the
CIBMTR between 2000 and 2011. Patients not responding (ie, patients not
achieving CR or partial remission [PR]) to the last salvage chemotherapy
before autologous HCT were excluded (n ¼ 58). Pediatric patients
(age < 18 years, n ¼ 2), patients with DLBCL representing transformation
from indolent histologies (n ¼ 18), and those receiving bone marrow grafts
(n ¼ 9) were not included in the analysis. DLBCL patients achieving CR with
ﬁrst-line rituximab-containing therapies and then undergoing upfront
autologous HCT consolidation, without ever experiencing rituximab failure
were also excluded (n ¼ 52). The ERF group consisted of the following: (1)
DLBCL patients with primary refractory disease after rituximab-based ﬁrst
chemo-immunotherapies (but eventually undergoing autologous HCT with
chemosensitive disease) and (2) patients who received rituximab-based
ﬁrst-line chemo-immunotherapies and then relapsed within 12 months of
initial diagnosis. The LRF group consisted of all other patients with che-
mosensitive disease at transplantation who received rituximab-containing
ﬁrst-line chemo-immunotherapies and then relapsed beyond 12 months
from initial diagnosis.
Study Endpoints
CR to salvage therapies was deﬁned as complete resolution of all known
disease on radiographic (computed tomography scan) assessments, whereas
CR undetermined represented patients meeting CR criteria with persistent
scan abnormalities of unknown signiﬁcance. PR required 50% reduction in
the greatest diameter of all sites of known disease and no evidence of dis-
ease progression. Primary outcomes were nonrelapse mortality (NRM),
progression/relapse, PFS, and OS. NRM was deﬁned as death from any cause
during the ﬁrst 28 days after transplantation or death without evidence of
lymphoma progression/relapse; relapse was considered a competing risk.
Progression/relapse was deﬁned as progressive lymphoma after HCT or
lymphoma recurrence after CR; NRM was considered a competing risk. For
PFS, a patient was considered a treatment failure at the time of progression/
relapse or death from any cause. For relapse, NRM, and PFS, patients alive
without evidence of disease relapse or progression were censored at last
follow-up. The OS was deﬁned as the interval from the date of trans-
plantation to the date of death or last follow-up. Neutrophil recovery was
deﬁned as the ﬁrst of 3 successive days with absolute neutrophil count 
500/mL after the post-transplantation nadir. Platelet recovery was consid-
ered to have occurred on the ﬁrst of 3 consecutive days with a platelet count
of 20,000/mL or higher, in the absence of platelet transfusion for 7 consec-
utive days. For neutrophil and platelet recovery, death without the event
was considered a competing risk.
Statistical Analysis
Probabilities of PFS and OS were calculated using the Kaplan-Meier
estimator with variance estimated by the Greenwood formula. Probabili-
ties of NRM, lymphoma progression/relapse, and hematopoietic recovery
were calculated using cumulative incidence curves to accommodate for
Table 1
Characteristics of 18-Year Old Patients Who Underwent Autologous
Transplantation for Relapsed/Refractory DLBCL after Rituximab-Containing
First-Line Chemo-Immunotherapy from 2000 to 2011 Reported to the
CIBMTR
Variable Early
Rituximab
Failure
Late
Rituximab
Failure
P
Value
No. of patients 300 216
Age at transplantation .004
Median (range), yr 58 (19-77) 62 (20-76)
18-29 yr 16 (5) 2 (1)
30-39 yr 18 (6) 10 (5)
40-49 yr 48 (16) 29 (13)
50-59 yr 84 (28) 47 (22)
60 yr 134 (45) 128 (59)
Male sex 189 (63) 129 (60) .450
Karnofsky performance
score
.257
<90% 95 (32) 54 (25)
90%-100% 185 (62) 146 (68)
Missing 20 (7) 16 (7)
Doxorubicin-containing
ﬁrst-line chemotherapy
277 (92) 204 (94) .215
Kinetics of relapse N/A
Primary refractory disease
(primary induction failure)*
150 (50) 0
12 mo from diagnosis to
initial relapse (early failure)
150 (50) 0
All others (late failure) 0 216
Rituximab received with
second-line chemotherapy
187 (62) 153 (71) .045
Time from diagnosis to initial
relapse, mo
<.001
Median (range) 8 (<1-12) 24 (12-125)
Disease stage at diagnosis .150
I-II 60 (20) 59 (27)
III-IV 219 (73) 143 (66)
Unknown 21 (7) 14 (6)
Disease status before HCT <.001
PR 199 (66) 68 (31)
CR 101 (34) 148 (69)
Aa-IPI score (before HCT) .001
Low 145 (52) 135 (68)
Low-intermediate 111 (40) 56 (28)
High-intermediate 25 (9) 6 (3)
High 0 1 (1)
Missing 19 18
History of bulky disease 29 (10) 10 (5) <.001
B symptoms at diagnosis 110 (37) 85 (39) .824
LDH elevated at diagnosis 83 (28) 48 (22) .324
Unknown 179 (60) 135 (63)
LDH elevated at transplantation 110 (37) 59 (27) .069
Unknown 34 (11) 32 (15)
Total no. of chemotherapy lines .526
Median (range) 2 (1-5) 2 (2-4)
2 161 (54) 122 (56)
>2 139 (46) 94 (44)
Extranodal involvement at any
time before HCT
198 (66) 140 (65) .488
CNS involvement at any time
before HCT
12 (4) 7 (3) .452
Bone marrow involvement at
any time before HCT
44 (15) 44 (20) .192
Missing 111 (37) 80 (37)
Radiation before HCT 102 (34) 65 (30) .349
Conditioning regimen .488
TBI-based without R 33 (11) 15 (7)
BEAMy and similar-with R 48 (16) 40 (19)
BEAMy and similar-without R 171 (57) 125 (58)
CBV or similar-with R 1 (<1) 0
CBV or similar-without R 34 (11) 26 (12)
BuMEL/BuCy-with R 0 2 (1)
BuMEL/BuCy-without R 9 (3) 6 (3)
Others-without Rz 4 (1) 2 (1)
Year of transplantation .680
(Continued)
Table 1
(continued)
Variable Early
Rituximab
Failure
Late
Rituximab
Failure
P
Value
2000 3 (1) 0
2001 4 (1) 3 (1)
2002 11 (4) 8 (4)
2003 11 (4) 7 (3)
2004 23 (8) 13 (6)
2005 36 (12) 14 (6)
2006 46 (15) 36 (17)
2007 45 (15) 35 (16)
2008 70 (23) 54 (25)
2009 31 (10) 27 (13)
2010 9 (3) 9 (4)
2011 11 (4) 10 (5)
Median follow up of survivors, mo 48 (3-147) 47 (3-126)
N/A indicates not available; aa-IPI, age-adjusted international prognostic
index; LDH, lactate dehydrogenase; CNS, central nervous system; TBI, total
body irradiation; R, rituximab; BEAM, carmustine, etoposide, cytrabine, and
melphalan; CBV, cyclophosphamide, carmustine and etoposide; BuMel,
busulfan and melphalan; BuCy, busulfan and cyclophosphamide.
Data presented are n (%), unless otherwise indicated.
* Primary refractory disease includes 23 patients with nonresponse (or
stable disease) to ﬁrst-line therapy, 28 patients with progressive disease
after ﬁrst-line therapy, and 99 patients not achieving a CR after ﬁrst-line
therapy (ie, primary induction failure-sensitive patient).
y BEAM and similar includes combination of BCNU or cyclophosphamide
or etoposide or melphalan or cytarabine.
z Others: Early failure: carboplatin þ thiotepa þ etoposide (n ¼ 3);
melphalan only (n ¼ 1). Late failure: melphalan only (n ¼ 1),
melphalan þ mitoxanterone (n ¼ 1).
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were compared between the ERF and LRF groups using the chi-square test
for categorical variables and the Wilcoxon 2-sample test for continuous
variables. Associations among patient-, disease-, and transplantation-
related variables and outcomes of interest were evaluated using
multivariate Cox proportional hazards regression. A stepwise selection
multivariate model was built to identify covariates that inﬂuenced out-
comes. Covariates with a P value <.05 were considered signiﬁcant. The
proportionality assumption for Cox regressionwas tested by adding a time-
dependent covariate for each risk factor and each outcome. Covariates
violating the proportional hazards assumption were stratiﬁed in the Cox
regression model. Results are expressed as relative risk (RR) or the relative
rate of occurrence of the event.
The variables considered in multivariate analysis included ERF versus
LRF (the main effect), age (considered as continuous and categorical), Kar-
nofsky performance status (KPS) at transplantation, disease stage at diag-
nosis, age-adjusted international prognostic index at the pre-HCT time
point, lactate dehydrogenase at diagnosis, number of lines of chemother-
apies before HCT, extranodal involvement at any time before HCT, bone
marrow involvement at any time before HCT, prior history of radiation
therapy, remission status at HCT (CR versus PR), and HCT conditioning
regimens. The potential interactions between the main effect and all sig-
niﬁcant covariates were tested and no interaction was detected.RESULTS
Patient-, Disease-, and Transplantation-Related
Variables
Between 2000 and 2011, 516 DLBCL patients receiving
rituximab-containing frontline chemo-immunotherapies
underwent autologous HCT. Three hundred patients are
included in the ERF group, whereas 216 constitute the LRF
cohort. One hundred and ﬁfty patients included in the ERF
group had primary refractory disease (Table 1), whereas an
additional 150 patients experienced relapse within
12 months from initial diagnosis. Median follow-up of sur-
vivors for the ERF and LRF groups was 48 months and
47 months, respectively. Completeness of follow-up at
3 years was 88% in both groups [12].
Figure 1. Autologous transplantation outcomes for DLBCL, relative to the timing of ri
disease progression/relapse, (C) PFS, and (D) OS. LRF is indicated by interrupted curv
Table 2
Outcomes after Autologous Transplantation
Outcomes Early Rituximab
Failure Prob
(95% CI)
Late Rituximab
Failure Prob
(95% CI)
Univariate
P Value
ANC .5  109/L, n 300 216
At 28 d 100 (97-100) 100 (97-100) .823
Platelet  20  109/L, n 293 212
At 28 d 82 (77-86) 85 (79-89) .394
At 100 d 94 (90-96) 98 (94-99) .022
NRM, n 297 214
At 1 yr 7 (5-11) 4 (2-7) .064
At 3 yr 9 (6-13) 9 (5-13) .795
At 5 yr 11 (8-16) 13 (8-19) .616
Progression/relapse, n 297 214
At 1 yr 40 (34-45) 27 (21-33) .003
At 3 yr 47 (41-52) 39 (33-46) .109
At 5 yr 49 (43-55) 43 (36-51) .258
PFS, n 297 214
At 1 yr 53 (47-58) 69 (62-75) .001
At 3 yr 44 (38-50) 52 (45-59) .085
At 5 yr 40 (34-46) 44 (36-51) .449
Overall survival, n 300 216
At 1 yr 62 (56-67) 85 (80-89) <.001
At 3 yr 50 (44-56) 67 (60-74) <.001
At 5 yr 47 (41-53) 54 (46-62) .179
ANC indicates absolute neutrophil count; Prob, probability.
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ntation-related characteristics of the 2 cohorts analyzed.
No signiﬁcant difference at baseline was observed be-
tween the 2 groups in terms of patient gender, KPS, disease
stage at diagnosis, lactate dehydrogenase level, bone
marrow or extranodal involvement, history of central
nervous system involvement, doxorubicin use in the
frontline setting, total lines of therapies before HCT, prior
radiation therapy, and types of HCT conditioning regimens.
Median age was signiﬁcantly different between the 2
cohorts (median age, ERF 58 years versus LRF 62 years; P ¼
.004). Compared with ERF, signiﬁcantly more patients in
the LRF cohort had low pre-HCT age-adjusted international
prognostic index score (52% versus 68%, P ¼ .001), received
rituximab-containing salvage (62% versus 71%, P ¼ .045),
and were in CR at the time of HCT (34% versus 69%,
P < .001).Hematopoietic Recovery
The cumulative incidence of neutrophil recovery at
dayþ28 was 100% (95% CI, 97% to 100%) for both ERF and LRF
cohorts (P ¼ .82) (Table 2). The cumulative incidence of
platelet recovery at day þ28 for ERF and LRF groups was 82%
(95% CI, 77% to 86%) and 85% (95% CI, 79% to 89%) (P ¼ .39),
respectively.tuximab failure. (A) Cumulative incidence of NRM, (B) cumulative incidence of
es; ERF, solid curves.
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Cumulative incidence of 3-year NRM was similar at 9%
(95% CI, 6% to 13%) for the ERF cohort and 9% (95% CI, 5% to
13%) for the LRF cohort (P ¼ .79) (Table 2, Figure 1A). On
multivariate analysis, KPS < 90 (RR, 2.03; 95% CI, 1.18% to
3.49%; P ¼ .01), age  60 years (RR, 1.82; 95% CI, 1.03% to
3.21%; P< .03), and history of bonemarrow involvement (RR,
1.96; 95% CI, 1.06% to 3.61%; P < .03) were associated with an
increased risk of NRM. ERF was not associated with NRM (RR,
1.31; 95% CI, .75% to 2.28%; P ¼ .34).
Progression/Relapse
Cumulative incidence of progression/relapse at 3 years
was 47% (95% CI, 41% to 52%) for the ERF cohort and 39% (95%
CI, 33% to 46%) for the LRF cohort (P¼ .10) (Table 2, Figure 1B).
In multivariate models, ERF displayed a time-varying effect
on the risk of lymphoma progression/relapse, with an
increased risk during the ﬁrst 6 months after autologous HCT
(RR, 2.86; 95% CI, 1.89% to 4.33%; P < .001). Beyond 6 months
after HCT, the risk of progression/relapse was similar be-
tween groups (RR, .68; 95% CI, .46-1.01; P ¼ .054). No other
variables were associated with increased risk for progres-
sion/relapse (Table 3).
PFS
Three-year PFS for the ERF group was 44% (95% CI, 38%
to 50%) compared with 52% (95% CI, 45% to 59%; P ¼ .08) in
the LRF group (Table 2, Figure 1C). On multivariate anal-
ysis, a time differential effect was noted on the risk of
treatment failure. An increased risk of treatment failure
(ie, inferior PFS) for the ERF cohort was apparent only
during the ﬁrst 9 months after autologous HCT (RR, 2.08;
95% CI, 1.52% to 2.85%; P < .001). Beyond 9 months afterTable 3
Multivariate Analysis
n
NRM
Main effect: ERF versus LRF 297 versu
Other signiﬁcant covariates
Karnofsky performance status at transplantation
90%-100% versus < 90% 328 versu
90%-100% versus unknown 328 versu
Age at transplantation: 60 versus <60 yr 258 versu
BM involvement at any time before HCT
No versus yes 235 versu
No versus missing 235 versu
Progression/relapse
Main effect: ERF versus LRF
6 mo within transplantation 297 versu
>6 mo beyond transplantation 157 versu
Treatment failure (PFS)
Main effect: ERF versus LRF
9 mo within transplantation 297 versu
>9 mo beyond transplantation 157 versu
Other signiﬁcant covariates
Karnofsky performance status at transplantation:
90%-100% versus < 90% 328 versu
90%-100% versus unknown 328 versu
Age at transplantation:  60 versus <60 yr 258 versu
Mortality (OS)
Main effect: ERF versus LRF
9 mo within transplantation 300 versu
>9 mo beyond transplantation 191 versu
Other signiﬁcant covariates
Karnofsky performance status at transplantation
90%-100% versus < 90% 149
90%-100% versus unknown 36
Age at transplantation:  60 versus < 60 yr 262 versuHCT, the risk of treatment failure was not signiﬁcantly
different between the ERF and LRF cohorts (RR, .71; 95% CI,
.47% to 1.07%; P ¼ .10). Other variables associated with
inferior PFS included KPS < 90 (RR, 1.33; 95% CI, 1.03% to
1.72%; P ¼ .02) and age  60 years (RR, 1.34; 95% CI, 1.06%
to 1.71%; P ¼ .01).
Subgroup analysis of the ERF cohort only showed that
patients with primary refractory disease had superior PFS
compared with ERF patients attaining a CR and then expe-
riencing relapse within 12months of initial diagnosis (3-year
PFS, 51% versus 37%, respectively; P ¼ .01) (Supplemental
Table S1, Figure 2A). This difference in PFS was, however,
not conﬁrmed on multivariate analysis (RR, .77; 95% CI, .57%
to 1.05%; P ¼ .10) (Supplemental Table S2).
OS
Three-year OS was signiﬁcantly better in LRF group at
67% (95% CI, 60% to 74%) compared with 50% (95% CI, 44% to
56%; P < .001) in the ERF group (Table 2, Figure 1D). On
multivariate analysis, the ERF cohort had an increased risk
of mortality during the ﬁrst 9 months after autologous HCT
(RR, 3.75; 95% CI, 2.38% to 5.92%; P < .001). Beyond
9 months after HCT, the risk of mortality was not signiﬁ-
cantly different between the ERF and LRF cohorts (RR, .86;
95% CI, .59% to 1.26%; P ¼ .43). Other variables associated
with inferior OS included KPS < 90 (RR, 1.50; 95% CI, 1.14% to
1.98%; P ¼ .004) and age  60 years (RR, 1.40; 95% CI, 1.07%
to 1.81%; P ¼ .01).
Among the ERF cohort, patients with primary refractory
disease had superior OS compared with ERF patients re-
lapsing within 12 months of initial diagnosis (3-year OS, 59%
versus 41% respectively; P ¼ .002) (Supplemental Table S1,
Figure 2B). This difference in OS was not conﬁrmed onRelative Risk (95% CI) P Value
s 214 1.31 (.75-2.28) .342
s 147 2.03 (1.18-3.49) .011
s 36 .31 (.04-2.26) .246
s 253 1.82 (1.03-3.21) .039
s 88 1.96 (1.06-3.61) .031
s 188 .51 (.26-1.02) .057
s 214 2.86 (1.89-4.33) <.001
s 151 .68 (.46-1.01) .054
s 214 2.08 (1.52-2.85) <.001
s 151 .71 (.47-1.07) .101
s 147 1.33 (1.03-1.72) .028
s 36 1.07 (.68-1.68) .777
s 253 1.34 (1.06-1.71) .017
s 216 3.75 (2.38-5.92) <.001
s 186 .86 (.59-1.26) .438
1.50 (1.14-1.98) .004
1.13 (.68-1.88) .629
s 254 1.40 (1.07-1.81) .013
Figure 2. (A) PFS and (B) OS of ERF DLBCL patients with primary refractory
disease (solid curve), compared with DLBCL relapsing within 12 months of
initial diagnosis (interrupted curve).
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Supplemental Table S2).Landmark Analysis
Landmark analysis of ERF and LRF patients alive and
progression free at 9 months after autologous HCT is
described in Supplemental Appendix and Figures 1S-2S.Causes of Death
Disease relapse and/or progression accounted for 72%
(n ¼ 112) mortality in the ERF cohort and 52% (n ¼ 63) in the
LRF cohort. Causes of death are summarized in Table 4.Table 4
Causes of Death
Early Rituximab
Failure
Late Rituximab
Failure
Number of deaths 155 82
Primary disease 112 (72) 52 (63.4)
Infection 7 (4.5) 4 (5)
Pulmonary complications 2 (1) 1 (1.2)
Graft-versus-host disease
(autologous)
0 2 (2.4)
Organ failure 12 (8) 10 (12)
Second malignancy 6 (4) 2 (2.4)
Hemorrhage 1 (.5) 0
Other/missing 15 (10) 11 (13.4)DISCUSSION
The aims of the present study were to examine outcomes
of DLBCL patients after autologous HCT relative to the pat-
terns of treatment failure after rituximab-containing upfront
therapies. This large cohort of DLBCL patients receiving
modern chemo-immunotherapies and who underwent
transplantation across multiple centers in a contemporary
era provides several important observations. First, relapsed
DLBCL patients experiencing LRF have excellent outcomes
after HDT and autologous HCT. Second, despite ERF, HDT can
provide durable disease control in almost one half of such
chemosensitive patients, underscoring its continued utility
in the current therapeutic armamentarium. Third, HDT is
appropriate for patients with primary refractory disease who
are responsive to subsequent salvage therapies. Fourth, our
analysis identiﬁes an extremely high (3- to 4-fold higher) risk
of lymphoma relapse and death in the initial 6 to 9 month
period after autologous HCT in the ERF cohort comparedwith
the LRF cohort. Following this timeframe, the risk of lym-
phoma progression/relapse and death were similar between
the cohorts.
The estimated 5-year PFS of LRF cohort of 44% in our
analysis is in line with historical rates observed in PARMA
trial (5-year event-free survival or 46%) [2] or in registry data
from the rituximab era [13], and it serves to endorse HDT as
the treatment-of-choice in such patients. The primary goal of
this analysis was to evaluate if autologous HCT can salvage a
subset of chemosensitive DLBCL patients with ERF. At the
outset, it is important to emphasize that the CIBMTR registry
does not capture information about relapsed DLBCL patients
who never underwent HCT (eg, because of lack of chemo-
sensitive disease) and that our study excluded DLBCL pa-
tients who received HCT with chemorefractory disease. The
dismal outcomes for such chemorefractory DLBCL patients
with or without HDT are, however, well known [9,13,14] and
not a subject of controversy. The primary message of our
study is that in chemosensitive DLBCL patients, despite ERF,
consolidation with autologous HCT is not an exercise in fu-
tility. This analysis provides critical data to validate current
practice and addresses concerns present in transplantation
community [8,10]. In fact, the 3-year PFS of 44% for the ERF
cohort of our study is comparable to the 3-year PFS of 68
CORAL study patients who actually underwent autografting
after ERF [11].
Early therapy failure, across hematological malignancies,
is a well-known surrogate marker of biologically more
aggressive disease and DLBCL is no exception. In fact, the
association of early relapse in DLBCL with inferior outcomes
is not uniquely limited to patients treated in rituximab era
and has also been seen in rituximab-naïve patients [15,16].
Even in our current analysis, although outcomes of ERF
cohort are encouraging, they clearly underperform when
compared with the LRF cohort. However, our data support
the concept that HCT should not be abandoned in this group
but can be used instead to form the basis of prospective
strategies to improve outcomes of these adverse-risk pa-
tients, including the following: (1) new modalities providing
high salvage therapy response rates in ERF DLBCL (to increase
patient pool eligible for HDT), and (2) peri-autologous HCT
therapy modiﬁcations to prevent disease relapse. The low
response rates (w40% to 45%) of ERF DLBCL to salvage che-
motherapies [11,17] often precludes HDT consolidation in
these patients. Evaluation of alternate salvage strategies
including novel antibody-based regimens [18], antibody-
drug conjugateebased regimens [19], or cytarabine-
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warrant investigation to improve response rates in these
adverse-risk patients.
For those ERF patients responsive to salvage therapies and
able to undergo HDT, the majority of the relapses appear to
happen early after HCT (progression/relapse rate of 40% at
1 year compared with 47% at 3 years, in our study), under-
scoring the need to provide better disease control in the
immediate post-transplantation period. The results of the
recent Blood and Marrow Transplant Clinical Trials Network
0401 study [21] suggest that mere intensiﬁcation of HCT
conditioning with radioimmunotherapy may not be the best
strategy to achieve this goal. The observation from our
multivariate analysis that differences in outcomes of ERF and
LRF are more pronounced during the ﬁrst 6 to 9 months after
HCT is hypothesis generating and argues for developing
strategies addressing the heightened treatment failure risk in
the early post-HCT period in ERF DLBCL patients. Although
results with post-HCT rituximab maintenance in relapsed
DLBCL in general have not been impressive [22], investiga-
tion of novel consolidation and/or maintenance strategies
(eg, programmed death-1 blockade [23], ibrutinib [24], PI3K
inhibitors [25]) for ERF DLBCL may improve HCT outcomes.
Allogeneic HCT is another modality that can potentially
improve outcomes of ERF patients. In a recent prospective
study, Glass et al. [26] reported 3-year OS of approximately
35% for aggressive B cell lymphoma patients with either
primary refractory disease or relapse within 12 months after
ﬁrst-line treatment (as opposed to < 12 months of initial
diagnosis in CORAL study and our analysis). In this study, the
authors did not report the outcomes of patients with che-
mosensitive and chemotherapy-unresponsive disease at the
time of HCT, separately. With this limitation in mind, the
3-year OS of 50% for ERF patients with chemosensitive
disease in our current report compares favorably with the
3-year OS of 35% (estimated from the ﬁgures in the
supplemental appendix of manuscript) in the study by Glass
et al. [26]. However, these data by Glass et al. are very
important, as they conﬁrm the prior observations of CIBMTR
registry studies, that allogeneic HCT can provide durable
disease control (3-year OS of w25% to 35%) in a subset of
DLBCL patients with either chemosensitive [27] or
chemotherapy-unresponsive disease [28] at transplantation.
The subgroup analysis of ERF cohort in our study showed
that patients with primary refractory disease had superior
OS and PFS compared with ERF patients attaining a CR and
then experiencing relapse within 12 months of initial diag-
nosis. However, it is important to highlight that after
adjusting for confounding variables in multivariate models,
this observation was not conﬁrmed. Baseline characteristics
of these 2 subgroups are shown in Supplemental Table S3.
Patients with primary refractory disease were signiﬁcantly
younger than those relapsing within 12 months of initial
diagnosis (median age, 56 versus 60 years, respectively; P ¼
.001). Because patient age was an independent predictor of
OS and PFS of these 2 subgroups on multivariate analysis
(Supplemental Table S2), it is possible that after adjusting for
age (and other covariates) in the multivariate model, the
observed differences in the OS and PFS seen on univariate
analysis between the ERF patients with primary refractory
disease versus those with early relapse was not conﬁrmed.
A number of biologic features impact DLBCL outcome,
including cell-of-origin [29] or c-myc expression [30];
however, these data are not available in the CIBMTR registry.
It, however, merits mention here that although cell-of-origin clearly affects the success of salvage chemo-
immunotherapies [20,31], its impact on the prognosis of
relapsed, chemosensitive DLBCL after autologous HCT has
not been demonstrated thus far [32-34]. Another possible
limitation of our data is lack of functional imaging (positron
emission tomography scanning) status before HCT [35]. It is
plausible that even among chemosensitive ERF DLBCL
patients, those achieving a positron emission tomogra-
phyenegative state may enjoy superior outcomes after HCT.
In conclusion, our analysis shows that autologous HCT
provides durable disease control in a clinically signiﬁcant
subset of chemosensitive DLBCL with ERF. These results are
practice validating and strongly support the continued use of
HDTas the treatment of choice in relapsed, chemoresponsive
DLBCL patients, regardless of the timing of relapse. Our data
identify the ﬁrst 6 to 9 months after HCT as a period of
heightened vulnerability to relapse and therapy failure,
where investigation of novel consolidation and/or mainte-
nance strategies is warranted.
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